Scarica l'app Stockscreener
155.80
5.82%
8.57
Dopo l'orario di chiusura:
155.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$147.23
Aprire:
$148.895
Volume 24 ore:
11.43M
Relative Volume:
1.57
Capitalizzazione di mercato:
$193.30B
Reddito:
$29.05B
Utile/perdita netta:
$8.11B
Rapporto P/E:
24.13
EPS:
6.4563
Flusso di cassa netto:
$9.16B
1 W Prestazione:
+6.54%
1M Prestazione:
+28.65%
6M Prestazione:
+29.33%
1 anno Prestazione:
+62.06%
Intervallo 1D:
$147.38
$157.29
Intervallo di 1 settimana:
$145.87
$157.29
Portata 52W:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
155.80 | 182.67B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,015.21 | 917.39B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
240.86 | 574.26B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
220.89 | 393.14B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
204.76 | 299.82B | 58.07B | 9.40B | 9.87B | 3.0115 |
|
NVS
Novartis Ag Adr
|
160.06 | 301.87B | 54.72B | 14.02B | 15.32B | 7.1855 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-08-19 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead Sciences (GILD) Net Margin Reset Challenges Slower Growth Narratives In FY 2025 Results - simplywall.st
Xilio Therapeutics Announces Pricing of Underwritten Offering - GlobeNewswire Inc.
Gilead Sciences Stock Spikes After Q4 Results: Time to Buy? - Yahoo Finance
Gilead Sciences Earnings Call: HIV Strength, New Catalysts - TipRanks
Gilead Accuses Cipla of Sidestepping Earlier Descovy Patent Deal - Bloomberg Law News
Yescarta Label Expansion And Dividend Growth Shape Gilead Investment Case - Yahoo Finance
Gilead Sciences, Inc. (NASDAQ:GILD) to Issue Dividend Increase$0.82 Per Share - MarketBeat
Key facts: Gilead Q4 profit hits $2.18B; signs MoU with UAE Health - TradingView
Morgan Stanley Sees Gilead Gaining Ground In HIV And Oncology - Finimize
TD Cowen Adjusts Gilead Sciences Price Target to $160 From $145, Maintains Buy Rating - marketscreener.com
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Truist Financial Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Buy Rating on Gilead: Solid Core Growth, Conservative Guidance, and Late-Stage Pipeline Upside Into 2026 - TipRanks
Gilead Sciences Poised for Yeztugo Execution, Pipeline Upside in 2026, Morgan Stanley Says - marketscreener.com
‘Pieces are coming together’ amid Gilead's Yeztugo launch: exec - Fierce Pharma
GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales - Finviz
GILD: Wells Fargo Raises Price Target for Gilead Sciences | GILD Stock News - GuruFocus
Gilead's Long HIV Patent Life and Emerging Oncology Portfolio Support a Wide Moat - Morningstar
Oppenheimer Adjusts PT on Gilead Sciences to $165 From $128, Maintains Outperform Rating - marketscreener.com
Truist Securities raises Gilead Sciences stock price target to $152 - Investing.com India
Gilead Sciences (NASDAQ:GILD) Hits New 1-Year High on Earnings Beat - MarketBeat
Gilead Sciences Stock Surges to Record Highs Amid Bull Notes - Schaeffer's Investment Research
Bernstein raises Gilead Sciences stock price target to $160 on growth outlook - Investing.com
Gilead Sciences stock holds steady as Goldman Sachs maintains Neutral rating By Investing.com - Investing.com India
Gilead Sciences stock hits all-time high at $153.32 By Investing.com - Investing.com India
Gilead Sciences stock hits all-time high at $153.32 - Investing.com
Gilead Sciences stock price target raised to $160 from $150 at BMO Capital - Investing.com
Gilead Sciences stock price target raised to $160 from $150 at BMO Capital By Investing.com - Investing.com India
Morgan Stanley Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
GILD: Scotiabank Raises Gilead Sciences Price Target Amidst Sect - GuruFocus
Gilead Sciences stock price target raised to $162 from $154 at BofA - Investing.com
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $177.00 - MarketBeat
Cantor Fitzgerald Boosts Gilead Sciences (NASDAQ:GILD) Price Target to $155.00 - MarketBeat
Gilead Sciences signs MoU with Ministry of Health and Prevention - ZAWYA
Gilead Analysts Boost Their Forecasts After Upbeat Q4 Earnings - Benzinga
Gilead Sciences (GILD) PT Raised to $162 at BofA Securities - StreetInsider
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $155 to $177 - 富途牛牛
GILD Analyst Rating: Needham Raises Price Target to $170 | GILD Stock News - GuruFocus
Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2025 Earnings Call Transcript - Insider Monkey
Gilead To Stay ‘Proactive And Disciplined’ With Deals But M&A Not Urgent Priority - BioSpace
Rhumbline Advisers Sells 15,602 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Needham & Company LLC Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Needham raises Gilead Sciences stock price target to $170 on strong HIV sales - Investing.com India
JPMorgan Adjusts Price Target on Gilead Sciences to $160 From $150, Maintains Overweight Rating - marketscreener.com
Wells Fargo Adjusts Price Target on Gilead Sciences to $165 From $150, Maintains Overweight Rating - marketscreener.com
Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $155 From $135, Maintains Overweight Rating - marketscreener.com
BMO Capital Adjusts Price Target on Gilead Sciences to $160 From $150, Maintains Outperform Rating - marketscreener.com
Scotiabank Adjusts Price Target on Gilead Sciences to $177 From $140, Maintains Sector Outperform Rating - marketscreener.com
Bernstein Adjusts Price Target on Gilead Sciences to $160 From $135, Maintains Outperform Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Gilead Sciences to $125 From $115, Maintains Neutral Rating - marketscreener.com
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.53%
0.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):